31127-39-6

Basic information

• Product Name: (E)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe
• Synonyms: (E)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe;2,3-Dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe
• CAS NO: 31127-39-6
• Molecular Formula: C₉H₉NO₃
• Molecular Weight: 179.17266
• Mol File: 31127-39-6.mol

Chemical Properties

• Boiling Point: 299.8°Cat760mmHg
• Flash Point: 135.1°C
• Appearance: /
• Density: 1.32g/cm³
• Vapor Pressure: 0.000521mmHg at 25°C
• Refractive Index: 1.588
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.33±0.14(Predicted)
• CAS DataBase Reference: (E)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe(31127-39-6)
• EPA Substance Registry System: (E)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe(31127-39-6)

Safety Data

• Hazardous Substances Data: 31127-39-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(E)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe is used as a versatile building block in organic synthesis for the creation of complex organic molecules. Its unique structure and functional groups allow for various chemical reactions, facilitating the synthesis of a wide range of compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (E)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe is used as a key intermediate in the development of new drugs. Its potential biological activities and structural features make it a promising candidate for the design and synthesis of novel therapeutic agents.
Used in Medicinal Chemistry:
(E)-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde oxiMe is employed as a valuable component in medicinal chemistry for the exploration of its potential applications in drug discovery. Its unique molecular structure and functional groups provide opportunities for the development of innovative pharmaceutical compounds with diverse therapeutic properties.

InChI:InChI=1/C9H9NO3/c11-10-6-7-1-2-8-9(5-7)13-4-3-12-8/h1-2,5-6,11H,3-4H2/b10-6-

Upstream product

• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 124362-47-6 3,4-Dihydro-2H-benzopyran-7-carbaldehyde 
• 941710-30-1 3,4-dihydro-2H-7-bromochromene 

Downstream Products

• 17413-10-4 2,3-dihydro-1,4-benzodioxin-6-ylmethylamine 
• 19102-07-9 2,3-dihydrobenzo[b][1,4]dioxine-6-carbonitrile 
• 31127-40-9 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methanamine hydrochloride 
• 1421869-62-6 C₂₇H₃₁FN₄O₃*ClH 
• 1421870-04-3 C₂₇H₃₁ClN₄O₃*ClH 
• 1421869-98-8 C₂₉H₃₆N₄O₃*ClH 
• 1421869-92-2 C₃₄H₃₆F₂N₄O₃*ClH 
• 1421869-86-4 C₂₇H₃₁FN₄O₃*ClH 
• 1421869-80-8 C₂₈H₃₄N₄O₄*ClH 
• 1421869-74-0 C₂₇H₃₁ClN₄O₃*ClH 
• 1421869-56-8 C₂₇H₃₂N₄O₃*ClH 
• 1421869-68-2 C₂₇H₃₁ClN₄O₃*ClH 
• 808740-73-0 3-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-isoxazole-5-carbaldehyde 

Relevant articles and documents

Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents

In this research several series of novel dioxygenated ring fused 4-anilinoquinazolines (10a-d) and 4-anilinoquinazoline-substituted triazole hybrid compounds (11–14) have been designed and synthesized. Their biological significance was highlighted by evaluating in vitro for anticancer activities, wherein several compounds displayed excellent activity specifically against three human cancer cell lines (KB, epidermoid carcinoma; HepG2, hepatoma carcinoma; SK-Lu-1, non-small lung cancer). Especially, compound 13a exhibited up to 100-fold higher cytotoxicity in comparison with erlotinib. Docking the most cytotoxic compounds (11d, 13a, 13b, and 14c) into the ATP binding site of different EGFR tyrosine kinase domains was perfomed to predict the analogous binding mode of these compounds to the EGFR targets.

Oxygen-containing benzo-cycloaliphatic amine compounds

The invention provides an oxygen-containing benzo-cycloaliphatic substituted amine compounds and application thereof and specifically relates to the oxygen-containing benzo-cycloaliphatic substitutedamine compounds as shown in a formula I which is described in the specification or pharmaceutically acceptable salts thereof and application of the same to preparation of Staphylococcus aureus goldenpigment synthesis inhibitor type antibacterial agents.

Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria

A novel series of coumarin derivatives 6a–o, bearing isoxazole moieties were designed and synthesized. After that, they were evaluated for melanin synthesis in murine B16 cells and inhibitory effect on the growth of CA (Candida albicans), EC (Escherichia coli), SA (Staphylococcus aureus). It was found that eleven compounds (6b–f, 6j–o) showed a better activity on melanin synthesis than positive control (8-MOP). Among them, compounds 6d (242%) and 6f (390%), with nearly 1.6 and 2.6-fold potency compared with 8-MOP (149%) respectively, were recognized as the most promising candidate hits for further pharmacological study of anti-vitiligo. Seven halogen substituted compounds exhibited moderate antimicrobial activity against CA. It is interesting that 6e–f and 6l–m, which had two halogens on the benzene showed a comparable activity with Amphotericin B against CA. The evaluation of melanin synthesis in B16 cells and inhibitory effect on bacteria of above structurally diverse derivatives had also led to an outline of structure-activity relationship.

Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition

Glycogen phosphorylase (GP) is a target for the treatment of hyperglycaemia in the context of type 2 diabetes. This enzyme is responsible for the depolymerization of glycogen into glucose thereby affecting the levels of glucose in the blood stream. Twelve

Synthesis and bioactivity of novel isoxazole chalcone derivatives on tyrosinase and melanin synthesis in murine B16 cells for the treatment of vitiligo

A new series of chalcone derivatives 1–18, bearing isoxazole moieties were designed and synthesized, and biologically evaluated for their activity on mushroom tyrosinase and melanin synthesis in murine B16 cells. The result indicated that most of prepared compounds 1–18 showed potent activating effect on tyrosinase, especially for 1–2, 4, 6–7, 9 and 15. Among them, compounds 2, 4 and 9 demonstrated the best activity with EC50?=?1.3, 2.5 and 3.0?μmol·L?1respectively, much better than the positive control 8-methoxypsoralan (8-MOP, EC50?=?14.8?μmol·L?1); In B16 cells, all the tested compounds exhibited a stronger activity on melanogenesis than 8-MOP (with the value of 115%). It was interesting that derivatives substituted with halogen (1, 2, 4, 5, 7, 9) were generally more potent. Compounds 2 (463%) and 18 (438%) with 3 and 4-fold potency compared with 8-MOP respectively, were recognized as the most promising candidate hits for further pharmacological study of anti-vitiligo.

Sodium nitrite-catalyzed aerobic oxidative Csp2-Csp3 coupling: Direct construction of the 4-aryldihydroisoquinolinone moiety

A bioinspired approach for the construction of the 4- aryldihydroisoquinolinone moiety via direct oxidative Csp2-Csp 3 coupling has been developed, which uses inexpensive sodium nitrite as catalyst and environmentally benign oxygen in the air as terminal oxidant.

Synthesis and biological evaluation of novel T-type Ca2+ channel blockers

A small molecule library of piperazinylalkylisoxazole derivatives containing about 600 compounds was designed, synthesized and evaluated for blocking effects on T-type Ca2+ channel. Several ligands were identified to possess high inhibitory activity against the T-type Ca 2+ channel. The compound 21 with trifluoromethyl substituents at C3-position of phenyl group (R1) and C2- position of phenyl group (R2) showed the highest inhibitory activity with IC50 value of 1.02μM, which is comparable to that of mibefradil.

Discovery of 3-amino-4-chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an isoxazoline library

In an effort to identify orally bioavailable factor Xa inhibitors, two isoxazolines libraries were prepared to scan for novel P1 ligands. From this work, 4-chloro-3-aniline was identified as a novel and potent benzamidine mimic.